Danimer Scientific, INC
Market Movers (8-K)
Danimer Scientific and its subsidiaries have filed for Chapter 11 bankruptcy to facilitate an orderly winddown and potential sale of assets.
Worse than expected
Capital raise
Danimer Scientific amends its financing agreement to improve liquidity and extends its forbearance agreement to March 31, 2025.
Danimer Scientific received notices of default and acceleration on its Senior Secured Note and Term Loan, subsequently entering into a forbearance agreement to temporarily prevent enforcement actions.
Worse than expected
Danimer Scientific's stock will be delisted from the NYSE due to not meeting market capitalization requirements and will begin trading on the OTCQX market.
Worse than expected
Danimer Scientific secured an $11.25 million loan and restructured its debt after facing default notices on previous credit agreements.
Worse than expected
Danimer Scientific has entered into retention agreements with its CFO, CMO, and Interim CEO, providing cash bonuses to ensure their continued service.
Quarterly Earnings (10-Q)
Danimer Scientific's Q3 2024 results show a decrease in revenue and a net loss, alongside concerns about the company's ability to continue as a going concern.
Worse than expected
Delay expected
Capital raise
Danimer Scientific's Q2 2024 results show a significant revenue decrease and a net loss, alongside strategic cost-cutting measures and a temporary suspension of a business segment.
Worse than expected
Delay expected
Capital raise
Danimer Scientific's first quarter 2024 results show a decrease in overall revenue, but an increase in PHA-based product sales, alongside cost-cutting measures and strategic financial moves.
Worse than expected
Delay expected
Capital raise
Annual Reports (10-K)
Danimer Scientific's 2023 annual report reveals a decrease in revenue and a net loss, alongside strategic efforts to manage costs and expand production capacity.
Delay expected
Capital raise
Worse than expected
Insider Trading (Form 4)
Michael A. Hajost, CFO of Danimer Scientific, reports the acquisition and disposal of Class A Common Stock and Restricted Stock Units.
Director David Jesse Moody reports the vesting of 646 restricted stock units into Class A Common Stock of Danimer Scientific on January 17, 2025.
Director Stephen Croskrey reports acquisition of 1,125 restricted stock units in Danimer Scientific, Inc.
Richard J. Hendrix, a director of Danimer Scientific, Inc., was granted 50,725 restricted stock units (RSUs) as part of director compensation.
Interim CEO Richard N. Altice was granted stock appreciation rights for 300,000 shares of Danimer Scientific's Class A common stock.
Director Richard J. Hendrix reports acquisition of stock appreciation rights in Danimer Scientific, Inc.
Proxy Statements (Def-14A)
Danimer Scientific is seeking stockholder approval for a reverse stock split to boost its stock price and maintain its listing on the New York Stock Exchange.
Danimer Scientific amends its proxy statement to reflect changes in voting standards for a share increase proposal and to disclose the retention of a proxy solicitor.
Danimer Scientific has filed definitive additional materials related to its proxy statement with the Securities and Exchange Commission.
Danimer Scientific's proxy statement outlines proposals for the annual stockholder meeting, including director elections, auditor ratification, and amendments to the certificate of incorporation and incentive plan.
Capital raise
Schedule 13G - Passive Investments
Armistice Capital, LLC and Steven Boyd have filed an amended Schedule 13G, disclosing a shared beneficial ownership of 9.99% of Danimer Scientific, Inc.'s Class A Common stock as of March 31, 2025.
Armistice Capital, LLC and Steven Boyd have filed an amended Schedule 13G, reporting a shared beneficial ownership of 5.50% of Danimer Scientific, Inc.'s Class A Common stock as of December 31, 2024.